-
Signals from muscle protect from dementia
03/26/2021
Scientists at St. Jude are studying how signals sent from skeletal muscle affect the brain.
-
Socioeconomic status plays a major role in cognitive outcomes
03/01/2021
St. Jude scientists are studying the risk factors associated with cancer treatments and its effects on cognition.
-
A genomic map to therapy-related blood cancers
02/12/2021
St. Jude scientists are studying mutations that lead to a certain kind of treatment-related blood cancer.
-
Challenging dogma about a relapsed brain tumor
01/27/2021
St. Jude scientists are studying the molecular mechanisms responsible for medulloblastoma treatment failure and recurrence.
-
Instruments err. This tool identifies the mistakes.
01/25/2021
St. Jude scientists created a free mathematical tool to find instrument-caused errors.
-
COVID-19 poses a serious risk to bone marrow transplant recipients
01/19/2021
St. Jude scientists are discovering that children and adults who receive bone marrow transplants should make COVID-19 prevention a priority.
-
Machine learning gives research a leg up
01/19/2021
St. Jude scientists developed deep learning to add to machine learning methods, which helps grow cancer research tools.
-
What’s to be learned by ‘painting’ the cancer genome? Plenty!
01/11/2021
St. Jude scientists have helped develop a web-based tool to offer researchers the ability to analyze genomic data which can improve future treatments.
-
Results published on medulloblastoma clinical trial
01/08/2021
St. Jude researchers find more insight into medulloblastoma molecular groups to determine treatment for patients.
-
Massive cloud eases genomic data sharing
01/06/2021
St. Jude researchers developed a cloud-based, data-sharing platform, which is the world’s largest pediatric cancer genomic data resource.
-
A fungal infection can kick off inflammation
12/02/2020
Scientists have found how A. fumigatus activates the inflammasome.
-
Researchers offer new strategy to stop COVID-19
11/18/2020
St. Jude scientists may have figured out how COID-19 kills and how to stop it.
-
Researchers look to flu to better understand how the body fights COVID-19
11/13/2020
St. Jude scientists teamed up with those at Washington University School of Medicine in St. Louis to compare how the disease-fighting immune system combats the flu and COVID-19.
-
Why do many drugs work in the lab but fail to get to the clinic?
11/04/2020
Researchers identify new forms of membrane proteins that offer drug development targets to minimize medication side effects.
-
How do neurons develop?
10/28/2020
St. Jude researchers are studying the Siah2 protein to determine how brain cells mature.
-
Protecting the lungs after flu and other respiratory infections
10/28/2020
St. Jude researchers have discovered cells that help regulate inflammation.
-
Ultra-high field NMR device adds to understanding of drug resistance
10/01/2020
Scientists at St. Jude used the most powerful NMR device in the United States to study a protein that drives some leukemias.
-
Study reveals structure of DUOX1 complex
09/15/2020
Researchers are learning more about how DUOX1 complex contributes to disease.
-
Computational tool helps to illuminate hidden mutations
07/06/2020
St. Jude researchers developed a powerful tool that can identify cancer-causing mutations in genomes.
-
CHANGE-Seq tool helps target genome editing
06/15/2020
St. Jude scientists create more scalable tools to study genome-editing methods.
-
Combination therapy holds promise for rare immune disorder
06/12/2020
Recent research shows how an overactive immune system produces too many cytokines in HLH.
-
Predicting secondary cancer risk in childhood cancer survivors
06/04/2020
St. Jude scientists are studying the effect of cancer treatments and inherited mutations in DNA-repair genes.
-
Caspase-8 triggers inflammatory signaling in multiple ways
05/18/2020
Beyond its role in cell death, St. Jude scientists have uncovered how caspase-8 contributes to inflammation.
-
Scientists study how bacteria evolve to resist antibiotics
05/11/2020
Researchers at St. Jude contribute to a study of bacteria and its evolving resistance to antibiotics.
-
Research reveals complexity of phase separation
05/06/2020
St. Jude researchers contribute to studying the nucleolus to learn more about phase separation.
-
Fine tuning phase separation
04/16/2020
Studying the interactions between proteins and RNA which define phase separation, St. Jude researchers were able to determine how each protein contributes.
-
Unraveling the mysteries of caspase-6
04/15/2020
St. Jude researchers discovered possible new ways to fight viruses and inflammatory illnesses.
-
Expanding ways to tame a global childhood killer
04/07/2020
A new anti-malarial drug offers hope for children suffering from Malaria.
-
Inherited mutation can drive SHH medulloblastoma
04/01/2020
Researchers find connections to inherited genetic mutations to a type of brain tumor. The study suggests certain genes should be included in routine testing.
-
The role of oxygen in wiring the brain
03/16/2020
Scientists at St. Jude are studying the role oxygen plays in the maturation and migration of neurons and have identified a new mechanism that helps control these processes.
-
Push to restore leukemia treatment effectiveness gains ground
03/09/2020
St. Jude Children’s Research Hospital scientists developed a way to discover the genes responsible for resistance to steroids in leukemia patients.
-
Obesity linked to severity and longer duration of flu
03/03/2020
New research suggests that obesity may be linked to increased severity and longer duration of the flu as well as higher amounts of flu in the body.
-
Predicting protein phase separation
02/06/2020
St. Jude has developed a way to predict how proteins phase separate. The answer will help scientists studying how these proteins contribute to disease.
-
How MAGE-A11 gene drives cancer revealed
01/21/2020
Results show a gene that drives cancer by promoting alternative polyadenylation
-
Chinese collaboration yields results
01/16/2020
St. Jude is working with the Chinese Children’s Cancer Group to lead the first Phase III clinical trial comparing targeted therapies for a high-risk type of leukemia.
